- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07938515
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations for DA-302168S in subjects with renal impairment.
Přehled studie
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: xiaolong qin
- Telefonní číslo: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
Studijní místa
-
-
Jiangsu
-
Suzhou, Jiangsu, Čína, 215000
- Nábor
- The Second Affiliated Hospital of Soochow University
-
Kontakt:
- xiaolong qin
- Telefonní číslo: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age 18-65 years inclusive at ICF signing, male or female; age matching (±10 years) between normal and renal impairment groups, with sex matching as far as possible (±1 participant per sex).
- Weight and BMI at screening: male ≥50.0 kg, female ≥45.0 kg; BMI 19.0-30.0 kg/m² inclusive; weight matching (±10 kg) between normal and renal impairment groups.
- Fertile female or male participants must agree to use reliable contraception for themselves and their partners during the study and for 90 days after dosing (see Appendix 3), and must not donate sperm or oocytes/eggs for assisted reproduction.
- Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with protocol requirements and complete the related procedures.
Exclusion Criteria:
- History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or screening serum calcitonin ≥50 ng/L.
- History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
- History of acute gallbladder disease within 3 months before ICF signing.
- Any malignancy within 5 years before ICF signing (except curatively treated basal cell carcinoma considered cured).
- History of severe cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, or other systemic disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
- Investigator-judged dysphagia at screening, or conditions possibly affecting drug absorption, distribution, metabolism, or excretion (e.g., active inflammatory bowel disease, gastrectomy, any intestinal resection).
- Severe hypoglycemia within 3 months before screening.
- Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug <5 half-lives before screening.
- History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance/allergy to GLP-1 receptor agonists.
- Major surgery within 1 year before screening [major surgery defined as surgery on intracranial, thoracic, abdominal, pelvic, or limb organs causing major tissue trauma and requiring prolonged recovery (e.g., organ transplantation, cardiac surgery, joint replacement)], or planned surgery during the study.
- Blood donation or massive blood loss (≥400 mL) within 3 months before screening or between screening and first dose, or planned blood donation during the study.
- History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDMA, cocaine) or positive baseline urine drug test.
- Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, or inability to abstain during the study.
- History of alcohol abuse within 1 year before screening (male >14 standard units/week, female >7 standard units/week; 1 standard unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive baseline breath/blood alcohol test.
- Special dietary requirements and inability to accept a standardized diet.
- Consumption of grapefruit-rich beverages or foods within 7 days before first dose, or unwillingness to stop during the study.
- Vaccination within 30 days before dosing, or planned vaccination within 30 days after dosing.
- Inability to avoid strenuous exercise or other behaviors possibly affecting PK parameters from 48 h before dosing through the study.
- History of needle/blood phobia, difficult blood collection, or intolerance to venipuncture.
- Pregnant or lactating women.
- Participant is an investigator or other related research staff for this project.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Group A
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Experimentální: Group B
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Komparátor placeba: Group C
Subjects with normal renal function matched to renal impairment subjects |
Small molecule GLP-1RA tablet |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Peak Plasma Concentration (Cmax) of DA-302168S
Časové okno: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
|
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168S
Časové okno: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2026-CP-DA168-14
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .